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dObjective: To perform a cost-effectiveness evaluation from the per-
spective of the Brazilian National Health System of alternatives strat-
egies (i.e., conventional interferon, pegylated interferon, and lamivu-
dine) for the treatment of patients with chronic hepatitis B who present
elevated aminotransferase levels and no evidence of cirrhosis at the
beginning of treatment. Methods: A Markov model was developed for
chronic hepatitis B (hepatitis B antigen e [HBeAg] positive and negative)
with 40 years’ time horizon. Costs and benefits were discounted at 5%.
Annual rates of disease progression, costs due to complications, and
the efficacy of medicines were obtained from the literature. One-way
and probabilistic sensitivity analysis evaluated uncertainties.
Results: For HBeAg positive patients, peginterferon (48 weeks) resulted
in an increase of 0.21 discounted life-years gained compared to inter-
feron (24 weeks). The incremental cost-effectiveness ratio (ICER) con-
verted to US dollars using the 2009 purchasing power parity conversion
factor was US$100,752.24 per life-year gained. For HBeAg negative pa-
tients, it was observed that interferon (48 weeks) compared with long-gained and ICER of US$15,766.90 per life-year gained. In the sensitivity O
e no
ntôni
al So
oi:10.1016/j.jval.2011.05.011nalysis, the ICER was more sensitive to variation in the probability of
ransition from chronic hepatitis B to compensated cirrhosis, discount
ate, and medicine prices. Cost-effectiveness acceptability curve for
BeAg positive (pegylated interferon vs. conventional interferon) and
egative (conventional interferon vs. lamivudine) showed that conven-
ional interferon was cost-effective until three times the gross domes-
ic product per capita.Conclusions: For patients with chronic hepatitis
with elevated aminotransferase levels in the pretreatment and no
irrhosis who were HBeAg positive, pegylated interferon (48 weeks)
rovided more life-years gained when compared to conventional inter-
eron (24 weeks), and the ICER surpasses the country’s buying power,
hich makes conventional interferon the chosen alternative. For
BeAg negative patients, conventional interferon (48 weeks) compared
o lamivudine provided more life-years gained at a favorable ICER.
eywords: chronic hepatitis B, cost-effectiveness, interferon, lamivu-
ine, peginterferon.term lamivudine presented an increase of 0.45 discounted life-years Copyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Hepatitis B is one of the most common infectious diseases
worldwide. An estimated 350 million people worldwide are
chronically infected with hepatitis B virus (HBV) [1]. In Brazil, at
least 15% of the population has been in contact with HBV and 1%
present with chronic disease [2]. Persistently high HBV DNA
levels are associated with an increased risk of cirrhosis and
hepatocellular carcinoma (HCC) [3,4], which contributes to the
increase of treatment costs due to morbidity [5].
Until recently and according to the Clinical Protocols and
Therapeutic Guidelines for High Cost Medications of the Brazil-
ian Ministry of Health [6], pharmacological options for the treat-
ment of chronic hepatitis B were restricted to interferon and
lamivudine. Currently, three antiviral medications (tenofovir,
entecavir, and adefovir) have extended the treatment alterna-
tives for the control of HBV action [7].
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ublished by Elsevier Inc.In a systematic review [8], it was observed that interferon
(IFN) presented the advantages of long-term response in hepa-
titis B antigen e (HBeAg) positive patients, a short treatment
duration and absence of resistance. The main advantages of
pegylated interferon (PEG-IFN) were its extended biological ef-
fect and the lower number of treatments it required. Both treat-
ment options showed the disadvantages of limited use in pa-
tients with a lower alanine aminotransferase (ALT) level at
pretreatment or with a decompensated liver, their association
with several adverse events and the inconvenience of subcuta-
neous injection.
The first nucleoside analogue to be approved and used for HBV
was lamivudine (LAM) [9], which is associated with minimal ad-
verse events, low maintenance response rates, and a need for
long-term therapy [10]. Its greatest limitation is the selection of
resistant mutants, with patients becoming resistant after a year of
treatment [11].
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S25V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) S 2 4 – S 2 8The objective of this study was to perform a cost-effectiveness
evaluation from the perspective of the Brazilian Public Health Sys-
tem (SUS) of alternative strategies (IFN, PEG-IFN, and LAM) for the
treatment of patients HBeAg positive and negative (i.e., antibodies
to HBeAg), who present high ALT levels and no evidence of cirrho-
sis at the beginning of treatment. This group of patients was cho-
sen because it is considered to represent the most prevalent and
clinically relevant chronic HBV infection.
Methods
Decision analysis software (DATA, version 1.3.1, Tree Age soft-
ware, Inc., Williamstown, MA) was used for the cost-effectiveness
analysis aimed at evaluating a hypothetical cohort of patients
with chronic HBV infection with a histological diagnosis of the
disease, positive for serum hepatitis B surface antigen for more
than 6 months, with detectable HBV DNA levels and high ALT
levels (more than twofold the upper normal limit [UNL]) and no
clinical or histological evidence of cirrhosis. Clinical research
shows differences in the age profile among HBeAg positive and
negative patients [12,13]. As a result, two models were built, con-
sidering the average age at the onset of treatment as 32 years for
HBeAg positive patients [12,14] and 40 years for HBeAg negative
atients [14]. A Markov model was used with 1-year cycles and
oth models evaluate short-course and longer duration treat-
ents with time-horizon of 40 years, given that most of the pa-
ients in the cohort would be dead after this period.
Ideally, economic analysis should be established prospectively,
nd together with the results of clinical research. The disease pro-
ression involves decades and it is difficult to realize prospective
tudies. The model parameters, including efficacy/effectiveness
easures were obtained from a specific systematic review [8] and
rom review of selected studies.
The efficacy measures used were: 1) HBeAg positive patients:
BeAg seroconversion; and 2) HBeAg negative patients: response
o treatment [low levels of HBV DNA ( 300–400 copies/mL) and
ormalisation of ALT levels] [13]. The long-term results were mod-
lled using the stages in the Markov model considering the annual
ailure in the durability of HBeAg seroconversion and treatment
esponse.
In this study, like previous economic analyses of antiviral
reatment for chronic hepatitis B [15], HBeAg seroconversion was
sed as a treatment-stopping criterion. However a patient could
xperience a relapse and return to the chronic hepatitis B stage
16]. For HBeAg negative patients, sustained remission was also
ot considered common [17].
The model did not assume any explicit consideration in regard
o LAM resistance. However, some effects of resistance to the
edication were captured with the reduction in long-term sero-
onversion rates [15].
HBeAg positive
The model consisted of six disease stages (Fig. 1A in Supplemen-
tary Materials found at: doi:10.1016/j.jval.2011.05.011). The model
structure was adapted from the model of Crowley et al. [18].
All patients in the model started at the chronic hepatitis B dis-
ase stage with no cirrhosis and received treatment alternatives.
he model evaluated short-term treatment for HBeAg positive pa-
ients: IFN dosed at 9 to 10 MU three times a week (24 weeks),
EG-INF alfa 2a (180 g) once a week (48 weeks) or long-term LAM
100 mg) daily (LAM use after 4 years of treatment in patients who
id not undergo HBeAg seroconversion did not bring any added
enefit; however, in the Markov model, these patients continued
o receive LAM and the cost was calculated in subsequent years).
he model doesn’t assume rescue therapy in case of treatmentailure associated with emergence of drug-resistant virus.Efficacy measures were obtained for 1 year of treatment con-
idering results from clinical research in patients with ALT levels
reater than or equal to twice the UNL, HBeAg seroconversion
ates for IFN (24%) [18], LAM (19%) [12], and PEG-IFN (32%) [12]. The
seroconversion estimates sustained for LAM for the second, third,
and fourth year of treatment were 10%, 6%, and 5%, respectively,
based on observational studies [12,19,20]. The rate of seroconver-
sion observed in the fourth year (5%) [20] was used from the fifth
year onward (Table 1 in Supplementary Materials found at: doi:
10.1016/j.jval.2011.05.011).
In all therapeutic alternatives, after treatment cessation, all
patients could experience a relapse. Van Nunen et al. [21] and
Wang et al. [22] demonstrated a 35% relapse for LAM in patients
with ALT levels greater than or equal to two to five times the UNL
6 months after the treatment; that rate was considered until the
fourth year of treatment. For the fifth year, a relapse of 25% was
estimated considering the potential long-term impact on the du-
rability of seroconversion [21,22]. Spontaneous seroconversion
rates of 9% were considered for patients in the beginning of the
treatment with PEG-IFN and IFN [18] (Table 1 in Supplementary
Materials found at: doi:10.1016/j.jval.2011.05.011).
There was limited published data on the annual loss of re-
sponse following treatment with PEG-INF, so cconservative re-
lapse rates of 8% were used in the analysis for IFN and PEG-IFN
[21], despite PEG-IFN has showed fewer relapses than conven-
tional IFN (Table 1 in Supplementary Materials found at: doi:
10.1016/j.jval.2011.05.011). All the efficacy assumptions for LAM
and PEG-INF are similar to what was used by Veenstra et al. [14];
thus, relapse rates for INF and PEG-INF were obtained in the same
study. The annual rates of disease progression or effectiveness
measures were described in Table 2 in Supplementary Materials
found at: doi:10.1016/j.jval.2011.05.011.
HBeAg negative
All HBeAg negative patients in the model started at chronic hepa-
titis B disease stage with no cirrhosis. The model consisted of six
disease stages (Fig. 1B in Supplementary Materials found at: doi:
10.1016/j.jval.2011.05.011). The treatment alternatives considered
were IFN at a dosage of 9 to 10 UM three times a week (48 weeks),
PEG-IFN (48 weeks) once a week, or long-term LAM daily (until the
patient responds to treatment).
To obtain efficacy measures, the estimates for sustained com-
bined response (suppression of HBV DNA and ALT normalization)
6 months after the treatment was stopped were derived from the
randomized controlled trial by Marcellin et al. [13] that compared
PEG-IFN with LAM (48 weeks). The response rates for PEG-IFN were
36% at the end of treatment and at follow-up and 69% for LAM at
the end of treatment. There is some data in the literature on re-
lapse rates after 6 months of treatment with LAM, but two studies
pointed out that the combined response rates were around 11% to
20% 1 to 2 years after treatment [23,24]. These authors reported
relapse rates of 83% after 6 months and after a year of follow-up
[23,24]. Based on these data, a conservative annual rate of relapse
of 80% for LAM was considered. For IFN, a complete response rate
to the treatment of considered 60% [25].
There are no long-term data on combined response for PEG-IFN
and there are few for IFN. One study suggested that 50% of patients
treated with IFN experienced relapse between 6 months and 32
months post treatment [26]. Considering that there were no re-
lapses 6 months after treatment with PEG-IFN [13], a relapse of 25%
was assumed after 6 months of treatment [27]. Spontaneous re-
lapses of 6% were considered [28,29]. These estimates were ob-
tained from Veenstra et al. [27]. The annual rates of disease pro-
gression or effectiveness measures are described in Table 2 in
Supplementary Materials found at: doi:10.1016/j.jval.2011.05.011.
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Only direct costs were taken into account in this study. All costs
were originally calculated in the national currency (Brazilian real
[BRL]). These values were converted to US dollars using the 2009
purchasing power parity (PPP) conversion factor according to the
International Monetary Fund. It was assumed 2009 PPP conversion
factor (US$1  1.56 BRL).
Prices of the medication therapies
Prices were based on the list of medication prices from the Medi-
cation Market Regulating Chamber (Câmara de Regulação do Mer-
cado de Medicamentos) on November 13, 2009. The average fac-
tory price was used with a state tax on goods and services of 0%
and the price adjustment coefficient of 24.92%, which is a manda-
tory minimum discount that affects the factory price of some
medications purchased by public entities. The average prices were
of US$51.42 (US$87.87–US$110.85) for IFN, US$578.69 (US$338.69–
US$730.02) for PEG-IFN and US$1.39 (US$0.43–US$2.16) for LAM.
The calculation of the minimum and maximum prices used the
lowest and the highest price found in the Medication Market Reg-
ulating Chamber table and then applied the price adjustment co-
efficient. Because there was no price variation for the PEG-IFN, the
same variation found for the IFN was used.
Annual costs due to chronic hepatitis B complications
Annual costs per patient with compensated cirrhosis (CC), decom-
pensated cirrhosis, and HCC were obtained from the study by Cas-
telo et al. [30] that evaluated the chronic hepatitis B costs in 2005 in
Brazil with a Delphi panel of specialists. The direct costs included
those generated by medical fees, lab exams, diagnostic and ther-
apeutic procedures, hospitalizations, and medications. Data on
costs were predominantly obtained from SUS billing tables and
medication prices. The annual costs of the evolving chronic hep-
atitis B stages were updated to 2009 and estimated as follows:
chronic hepatitis B (US$870), CC (US$1243), decompensated cirrho-
sis (US$7763), and HCC (US$1679).
Cost-effectiveness analysis
The Markov model was used to estimate the clinical benefits in
life-years gained (LYG) and the costs of the medication alterna-
tives in the time horizon period. The comparison among the treat-
ment alternatives was measured by the incremental cost-effec-
tiveness ratio (ICER). The cost-effectiveness threshold developed
by the World Health Organization [31] is one to three gross domes-
tic product (GDP) per capita for an additional disability adjusted
life year prevented. A discount rate of 5% per year was adopted for
the costs and results.
A unidirectional sensitivity analysis was conducted to deter-
mine the impact in the ICER estimate. This analysis was carried
out by changing individual inputs: therapy response at the first
year of treatment (interval confidence), prices of the medication
(lowest, highest), discount rates (0%, 5%, and 10%) or magnitude of
treatment effectiveness in a Tornado analysis. A probabilistic sen-
sitivity analysis was conducted and generated a cost-effectiveness
acceptability curve using Monte Carlo simulation methods. Trian-
gular distributions were assigned to probability based on the pa-
rameter ranges (minimum, maximum) listed in Table 2 in Supple-
mentary Materials found at: doi:10.1016/j.jval.2011.05.011.
Results
The clinical results and economic estimates for each medication
alternative (IFN, PEG-IFN, and LAM) for chronic hepatitis B treat-
ment are presented in Table 3 in Supplementary Materials found
at: doi:10.1016/j.jval.2011.05.011.In HBeAg positive patients, it was observed that PEG-IFN (48
weeks) resulted in more LYG compared to IFN (24 weeks), with a
difference of 0.21. The ICER was US$100,752.24 per LYG. The LAM
strategy was dominated. In the case of HBeAg negative patients, it
was observed that IFN (24 weeks) presented an ICER of
US$15,766.90 per LYG compared to LAM (lifetime), with a differ-
ence of 0.45 LYG. The LAM strategy and PEG-INF were dominated.
For HBeAg positive patients, the treatment with LAM resulted
in an average of 13.58 LYG compared to 14.25 LYG (IFN) and 14.46
LYG (PEG-IFN). The accumulated incidence of CC across 10 years
was 18%, 15%, and 14%, respectively. For HBeAg negative patients,
the treatment with IFN results in an average of 13.12 LYG com-
pared to 12.93 LYG (PEG-IFN) and 12.67 LYG (LAM). The incidence
accumulated of CC in 10 years was 22.7%, 23.3%, and 26%, respec-
tively.
Sensitivity analysis
For both groups, when the discounts (0%, 5%, and 10%) were ap-
plied to the costs, the ICER estimates decreased.
For HBeAg positive patients, when the worst and the best sce-
narios (minimum or maximum values of the seroconversion rates)
were modelled for the first year of treatment, there was no affect
on the ICER comparing PEG-INF versus INF.
For HBeAg negative patients comparing INF versus LAM, when
the best scenario (maximum value of response) was used for the
first year of treatment, we observed a reduction in the ICER
US$4894.87. Concerning the worst scenario, the ICER was not al-
tered. For HBeAg positive patients comparing PEG-INF versus INF,
when medicines minimum prices were applied to the medica-
tions, there was a decrease in the ICER US$57,341.40 and the ICER
increased (US$128,248.29) when maximum prices were applied.
The same phenomenon was observed for the HBeAg negative pa-
tients comparing INF versus LAM, with ICERs of US$4895.94 and
US$24,507.22, respectively.
The Tornado analysis demonstrated that the ICER estimates
were more sensitive to the variation in the probability of chronic
hepatitis B evolving to CC, seroconversion to CC and response to
CC (Figs. 2 and 3 in Supplementary Materials found at: doi:10.1016/
j.jval.2011.05.011).
For HBeAg positive patients, the cost-effectiveness acceptabil-
ity curve generated from the PSA for the discounted incremental
cost-effectiveness ratio indicated that INF was cost-effective com-
pared with PEG-INF until three GDP per capita. To willingness to
pay up than US$104,487.20, using the 2009 PPP conversion factor,
PEG-INF has up than 50% to be cost-effective compared with INF.
For HBeAg negative patients, INF was cost-effective compared
with LAM at the Brazilian threshold.
Discussion
In this study, for HBeAg positive patients, PEG-IFN when compared
to the IFN showed a little better result, but presented an ICER
above the current Brazil cost-effectiveness threshold. The ICER
was more sensitive to variation in the progression probability of
the chronic hepatitis B to CC and seroconversion for CC. Therapy
response did not impact the sensitivity analysis and can be related
to the small seroconversion interval observed in the literature.
Greater variation in the ICER was noticed when medication price
and discount rate was varied. In probabilistic sensitivity analysis,
INF was cost-effective compared with PEG-INF until three GDPs
per capita.
Using a Markov model system and data from clinical research,
Sullivan et al. [32] evaluated the ICER of treatment with PEG-IFN
compared to that of LAM in HBeAg positive patients from the per-
spective of Taiwan. Treatment with PEG-IFN was considered more
cost-effective considering factors such as disease progression,
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same variations observed in this study and was considered favor-
able because it was within the buying power parameters of that
country. Veenstra et al. [14] observed that even though PEG-IFN
was a more expensive alternative than LAM, it provided better
results in terms of health and cost-effectiveness within the buying
power constraints of the United Kingdom.
In our study, for HBeAg negative patients, INF compared to
LAM demonstrated more LYG and ICER within the buying power of
the country. The PEG-IFN alternative was dominated. In the sen-
sitivity analysis, we observed that varying the interval of the tran-
sition probabilities caused less variation in the ICER. Greater vari-
ation in the ICER was observed when medications price and
discount rate varied. In PSA, INF was cost-effective even for values
up to three GDPs per capita.
The results of our study show that the progression to CC in
HBeAg negative patients was higher than in HBeAg positive pa-
tients and that LAM resulted in greater progression in both groups.
Lacey et al. [16] observed similar results and concluded that short-
term treatment with IFN, PEG-IFN, or LAM presented limited influ-
ence on the disease progression.
Comparing PEG-IFN with LAM in HBeAg negative patients,
Veenstra et al. [27] demonstrated that PEG-IFN had incremental
enefits on life expectancy and quality of life with an acceptable
CER in Taiwan. Kanwal et al. [28] verified that IFN was more cost-
ffective compared to LAM in HBeAg negative patients. The au-
hors emphasized that IFN could reduce costs because it elimi-
ated the need for longer therapy and that it could be effective
hen it did not present viral resistance.
Some limitations to our study can be identified and they per-
ain to treatment compliance, patient profiles, natural history of
he disease, annual costs, time-horizon, no natural mortality
ates, and the estimates obtained in the literature. All long-term
odeling studies are inherent uncertainties in projecting long-
erm results.
The modelling did not consider the occurrence of problems in
ompliance with LAM long-term antiviral treatment, which can
enerate worse results than those observed in the clinical trials.
he same can be considered in the treatment with IFN due to
dverse events. Low adherence rates to the treatment can reduce
he therapy response, thereby risking the treatment’s effective-
ess on the disease progression.
The profile of the patients included in our study does not allow
or the extrapolation of the results to patients with a different
rofile. However, that choice was considered the most prevalent
nd clinically relevant form of chronic HBV infection. High levels
f ALT in the pretreatment is a predictable factor for the response
t the end of the treatment and that IFN may be adverse to pa-
ients in advanced stages of the disease [18]..
We assumed that patients in different stages of chronic hepa-
titis B present the same clinical course and progression rates as
nontreated patients. This condition is consistent with several pub-
lished analyses of cost-effectiveness, where the patients without
response and nontreated patients progress in a similar manner
[28,32,33].
In addition, the estimates in the literature are limited and in-
ternational studies that are mainly focused on Asian populations
are the main sources of findings on the medications used in the
treatment of chronic hepatitis B.
Conclusions
This analysis suggests that for HBeAg positive patients with high
levels of ALT in the pretreatment and without cirrhosis or HCC at
the beginning of the treatment, PEG-IFN (48 weeks) provided more
LYG when compared to IFN (24 weeks), but the ICER surpasses the
country’s buying power, which makes IFN the chosen alternativefor those patients. For HBeAg negative patients, INF (48 weeks)
compared to LAM (long-term) provided more LYG at an acceptable
ICER to the country. The sensitivity analyses show that the ICER
was more sensitive to variation in the probability of transition
from chronic hepatitis B to CC, discount rate, and medicine prices.
Our findings suggest that interferon could be considered the cho-
sen alternative in health care systems with limited resources.
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